As you have seen, it has been a very active time at Eton. During the call, we will review fourth quarter results, provide ...
Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2025 Earnings Call Transcript March 19, 2026 Eton Pharmaceuticals, Inc. misses on ...
Q4 2025 Earnings Call March 19, 2026 4:30 PM EDTCompany ParticipantsDavid Krempa - Chief Business OfficerSean Brynjelsen ...
Eton Pharmaceuticals Inc (ETON) reports an 83% revenue increase and unveils promising new products, despite rising expenses and cash outflows.
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity ...
Investor's Business Daily on MSN
Stock market today: Dow up as Trump says this; Cathie Wood snaps up IPO stock amid 84% dive (live coverage)
The Dow Jones rose after President Trump spoke on Iran. A pharma play tested an entry on the stock market today. Cathie Wood ...
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfuncti ...
Long-term lithium therapy remains the most effective maintenance treatment for bipolar disorder, yet it poses a significant ...
Eton Pharmaceuticals made waves in the rare disease space with its fourth quarter 2025 financial results, capping off an ...
B virus infection causes rapidly progressive meningoencephalitis and severe ocular involvement, including necrotizing chorioretinitis and uveitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results